

**REMARKS**


The above amendments have been made to place the application in a more traditional format.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS**

5. (Amended) A composition comprising the compound as claimed in [any one of claims 1 to 4] claim 1 and a pharmaceutically acceptable carrier.

10. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in medicine.

11. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in the preparation of a medicament for use in the treatment, prevention or reducing the risk of Gram negative septic shock or another disease state involving elevated cytokine levels.

12. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in the preparation of a medicament for use in the treatment, prevention or reducing the risk of viral infection.

13. (Amended) The use of a compound as claimed in [any one of claims 1 to 4] claim 1 in the preparation of a medicament for use in the treatment, prevention or reducing the risk of metastases or angiogenesis.